The United Kingdom has signed a new trade agreement with South Korea, projected to contribute an additional £400 million annually to its economy. This deal replaces the 2019 post-Brexit arrangement
Pharmaceutical
155Articles
The UK faces a surge in counterfeit weight loss injections as criminal groups target a lucrative and vulnerable market. Recent warnings from the pharmaceutical sector highlight an exponential rise in
Dame Emma Walmsley, departing chief executive of GSK, has emphasised the critical need for further improvements within the United Kingdom’s life sciences commercial environment. Speaking following the recent UK United
The pharmaceutical sector has welcomed the announcement by the Department of Health that the NHS rebate rate for newer medicines will fall to 14.5 per cent next year, down from
Illicit Weight Loss Drug Supplier Alluvi Persists with Unlicensed Sales After High Profile MHRA Raid
A company linked to the globe’s largest known seizure of illicit weight-loss medications remains active in the UK market despite regulatory intervention. Alluvi, the firm in question, continues to distribute
The United Kingdom is poised to provide NHS patients with access to new medicines previously deemed unaffordable under a sweeping agreement with the United States. Under the deal, NHS expenditure
Gilead’s TROP-2 drug Trodelvy misses its primary endpoint in a key phase 3 breast cancer trial, though early signs suggest possible survival benefits.
AstraZeneca has recorded its highest quarterly revenue to date, achieving a ten per cent increase and surpassing analyst expectations. The FTSE 100 pharmaceutical group announced total third quarter revenue had
The UK is facing mounting pressure from the United States to reform its drug pricing policies, with the US ambassador, Warren Stephens, delivering a stark ultimatum to government officials and
Kenvue, the American pharmaceutical firm behind the well-known paracetamol brand Tylenol, has been acquired for $49 billion (£37 billion) by consumer goods conglomerate Kimberly-Clark. The deal follows a tumultuous period
Two of the world’s largest pharmaceutical conglomerates have become embroiled in an escalating takeover battle for Metsera, an emerging biotech on the verge of breakthroughs in weight-loss drug innovation. Novo
The powerful Novo Nordisk Foundation, the largest shareholder in pharmaceutical giant Novo Nordisk, has executed a dramatic boardroom takeover after a sharp disagreement about the company’s strategic direction. The move,
AstraZeneca, the United Kingdom’s most valuable publicly listed company, has secured the backing of leading shareholder advisory groups for its proposal to achieve a direct listing on the New York
AstraZeneca has announced a major shift in its transatlantic pricing strategy, pledging to sharply reduce the cost of its medicines in the United States following mounting political pressure. The pharmaceutical
Senior figures within the British Medical Association (BMA) have ignited fierce debate following the leak of a letter suggesting that GPs should direct patients to A and E departments rather
Novo Nordisk, the Danish pharmaceutical giant best known for developing the weight-loss injection Wegovy, has announced a landmark deal to acquire US-listed biotech Akero Therapeutics for up to $5.2 billion.
